Eisler Capital Management’s Biogen BIIB Stock Holding History

Eisler Capital Management’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-5,200	Closed	-$780K	–	928
2024 Q4	$780K	Buy	+5,200	New	+$877K	﹤0.01%	707

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Eisler Capital Management's BIIB Position: Q1 2025 in Review

Eisler Capital Management sold out of Biogen (BIIB) in Q1 2025, closing a stake of 10,611 shares — an estimated $1.59M sold.

Eisler Capital Management first reported a position in BIIB in Q4 2024 and held it in 1 quarter. The position peaked at $1.59M in Q4 2024. 880 funds tracked by Wall St. Rank hold BIIB as of Q1 2025.

Eisler Capital Management reported no remaining Biogen position as of Q1 2025 after selling out during the quarter.
Eisler Capital Management sold 10,611 Biogen shares in Q1 2025, an estimated $1.59M.
Eisler Capital Management first reported a position in Biogen in Q4 2024 and held it in 1 quarter.
Eisler Capital Management's Biogen position peaked at $1.59M in Q4 2024.
880 funds tracked by Wall St. Rank held Biogen as of Q1 2025.

Based on Eisler Capital Management's 13F filing for Q1 2025, filed 14 May 2025.